Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / FDA Cracks Down on Precription Opioid Abuse

August 22, 2012

FDA Cracks Down on Precription Opioid Abuse

Last  month, the U.S. Food and Drug Administration (FDA) approved an initiative that aims to prevent future abuse of extended release and long-acting opioids. The program, known as a Risk Evaluation and Mitigation Strategy (REMS), primarily requires opioid manufactures to educate doctors about proper pain management, patient selection, and how to ensure that the benefits of the drug outweigh the risks.

Drugs like Oxycontin, Avinza, Dolophine, Duragesic, and eight other brand names are among the most commonly abused prescription drugs and tend to lead to overdoses, addiction, and thousands of deaths across the U.S.

The FDA estimates that 23 million people were prescribed ER/LA opioid drugs in 2011 and many are at high risk of abusing them because many people are not aware of the risks. FDA commissioner, Dr. Margaret Hamburg says, “The FDA’s goal with this risk evaluation and mitigation strategy approval is to ensure that health care professionals are educated on how to safely prescribe opioids and that patients know how to safely use these drugs.”

The FDA and the Obama administration aim to shed light on issues of misprescribing and overprescribing while improving awareness about the dangers of opioid drugs. Since July 9, 2012, the FDA is now notifying opioid makers that they must propose a REMS plan within 120 days. In hopes of tackling the prescription drug epidemic, the FDA wants the plan to include a way to keep track of whether the numbers of misuse, addiction, and mis-prescribed are coming down. Read more…

Gil Kerlikowske, director of the Office of National Drug Control Policy, said:

“We commend the FDA for taking action to save lives by increasing access to prescriber education. Since day one, the Obama Administration has been laser focused on addressing the prescription drug abuse epidemic and today’s action is an important contribution to this comprehensive effort.”

47.608945-122.332015

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Tagged: brain, Drug Abuse, Health Policy, Lifestyle and habits Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2023 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap